Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Studies have shown that venlafaxine improves post-traumatic stress disorder (PTSD). It may also be used for chronic neuropathic pain. It is taken orally (swallowed by mouth). It is also available as the salt venlafaxine besylate (venlafaxine benzenesulfonate monohydrate) in an extended-release formulation (Venbysi XR).
Common side effects include loss of appetite, constipation, dry mouth, dizziness, sweating, insomnia, drowsiness and sexual problems. Severe side effects include an increased risk of suicide, mania, and serotonin syndrome. Antidepressant withdrawal syndrome may occur if stopped. There are concerns that use during the later part of pregnancy can harm the baby. How it works is not entirely clear, but it seems to be related to the potentiation of the activity of some neurotransmitters in the brain.
Venlafaxine was approved for medical use in the United States in 1993. It is available as a generic medication. In 2022, it was the 44th most commonly prescribed medication in the United States, with more than 13 million prescriptions.
|
Read full article at Wikipedia
|
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 |
ZBMZVLHSJCTVON-UHFFFAOYSA-N |
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1 |
|
environmental contaminant
Any minor or unwanted substance introduced into the environment that can have undesired effects.
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
xenobiotic
A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
|
|
beta-adrenergic antagonist
An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drug
A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
|
|
View more via ChEBI Ontology
N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide
|
sotalol
|
ChemIDplus
|
sotalolum
|
ChemIDplus
|
4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide
|
ChemIDplus
|
β-cardone
|
ChemIDplus
|
Sotalol
|
KEGG COMPOUND
|
2464
|
DrugCentral
|
C07309
|
KEGG COMPOUND
|
D08525
|
KEGG DRUG
|
DB00489
|
DrugBank
|
HMDB0014632
|
HMDB
|
LSM-1465
|
LINCS
|
Sotalol
|
Wikipedia
|
View more database links |
2380820
|
Reaxys Registry Number
|
Reaxys
|
3930-20-9
|
CAS Registry Number
|
KEGG COMPOUND
|
3930-20-9
|
CAS Registry Number
|
ChemIDplus
|
20562595
|
PubMed citation
|
Europe PMC
|
21553267
|
PubMed citation
|
Europe PMC
|
21854895
|
PubMed citation
|
Europe PMC
|
|